PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 2nd, 2016 • Matinas BioPharma Holdings, Inc. • Pharmaceutical preparations • New York
This Placement Agency Agreement ("Agreement") sets forth the terms upon which Aegis Capital Corp., a New York corporation, and a registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") (the “Placement Agent”), shall be engaged by Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of shares (the “Series A Preferred Shares”) of Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), of the Company. Each Series A Preferred Share will (i) have a dividend of 8% per annum payable in shares of Common Stock (as defined below), to be accrued until conversion, (ii) have a liquidation preference of $5.00 per Series A Preferred Share, and thereafter will participate with the Common Stock, as such term is defined below, on an as-converted basis and (iii) be convertible into 10 shares (“Shares”) of common
FINDER’S AGREEMENTFinder’s Agreement • November 2nd, 2016 • Matinas BioPharma Holdings, Inc. • Pharmaceutical preparations • New York
This agreement (the “Agreement”) is entered into as of July 29, 2016 between Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”) and Aegis Capital Corp., a New York corporation (“Finder”).
